The non-competitive AMPA antagonist LY 300168 (GYKI 53655) attenuates AMPA-induced hippocampal injury in neonatal rodents

Neuroscience Letters

Volumn 235, Issue 1-2, 1997, Pages 93-97

  Liu, X H ^a   Wang, P ^a   Barks, J D E ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Amino 3 hydroxy 5 methyl 4 isoxazole propionate; Excitatory amino acid antagonist; Excitotoxicity; GYKI 53655; Hippocampus; Newborn

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ATROPHY; BRAIN INJURY; BRAIN SIZE; CELL LOSS; CELL MATURATION; CENTRAL NERVOUS SYSTEM; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; HIPPOCAMPUS; MACROGLIA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ATROPHY; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; INJECTIONS, INTRAPERITONEAL; N-METHYLASPARTATE; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030732277     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(97)00675-7     Document Type: Article

References (22)

1. Barks J.D., Nair M.P., Schwartz S.A., Silverstein F.S. Potentiation of N-methyl-D-aspartate-mediated brain injury by a human immunodeficiency virus-1-derived peptide in perinatal rodents. Pediatr. Res. 34:1993;192-198.
2. Barks J.D., Silverstein F.S. Excitatory amino acids contribute to the pathogenesis of perinatal hypoxic-ischemic brain injury. Brain Pathol. 2:1992;235-243.
3. Chizh B.A., Cumberbatch M.J., Headley P.M. A comparison of intravenous NBQX and GYKI 53655 as AMPA antagonists in the rat spinal cord. Br. J. Pharmacol. 112:1994;843-846.
4. David J.C., Yamada K.A., Bagwe M.R., Goldberg M.P. AMPA receptor activation is rapidly toxic to cortical astrocytes when desensitization is blocked. J. Neurosci. 16:1996;200-209.
5. Donevan S.D., Rogawski M.A. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, non-competitive antagonist of AMPA/Kainate receptor responses. Neuron. 10:1993;51-59.
6. Donevan S.D., Yamaguchi S., Rogawski M.A. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity. J. Pharmacol. Exp. Ther. 271:1994;25-29.
7. Eckstein J.A., Swanson S.P. Determination of a novel α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor antagonist (LY300164) and its N-acetyl metabolite in mouse, rat, dog and monkey plasma using high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B. 668:1996;153-158.
8. Ikonomidou C., Mosinger J.L., Salles K.S., Labruyere J., Olney J.W. Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-aspartate neurotoxicity. J. Neurosci. 9:1989;2809-2818.
9. Johansen T.H., Chaudhary A., Verdoorn T.A. Interactions among GYKI-52466, cyclothiazide, and aniracetam at recombinant AMPA and kainate receptors. Mol. Pharmacol. 48:1995;946-955.
10. Le Peillet E., Arvin B., Moncada C., Meldrum B.S. The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat. Brain Res. 571:1992;115-120.
11. + currents in hippocampal neurons. Soc. Neurosci. Abstr. 20:1994;1537.
12. May P.C., Robison P.M. GYKI 52466 protects against non-NMDA receptor-mediated excitotoxicity in primary rat hippocampal cultures. Neurosci. Lett. 152:1993;169-172.
13. McDonald J.W., Roeser N.F., Silverstein F.S., Johnston M.V. Quantitative assessment of neuroprotection against NMDA-induced brain injury. Exp. Neurol. 106:1989;289-296.
14. McDonald J.W., Silverstein F.S., Johnston M.V. Neurotoxicity of N-methyl-D-aspartate is markedly enhanced in developing rat central nervous system. Brain Res. 459:1988;200-203.
15. McDonald J.W., Silverstein F.S., Johnston M.V. Neuroprotective effects of MK-801, TCP, PCP and CPP against N-methyl-D-aspartate induced neurotoxicity in an in vivo perinatal rat model. Brain Res. 490:1989;33-40.
16. McDonald J.W., Trescher W.H., Johnston M.V. Susceptibility of brain to AMPA induced excitotoxicity transiently peaks during early postnatal development. Brain Res. 583:1992;54-70.
17. Moncada C., Arvin B., Le Peillet E., Meldrum B.S. Non-NMDA antagonists protect against kainate more than AMPA toxicity in the rat hippocampus. Neurosci. Lett. 133:1991;287-290.
18. Moudy A.M., Yamada K.A., Rothman S.M. Rapid desensitization determines the pharmacology of glutamate neurotoxicity. Neuropharmacology. 33:1994;953-962.
19. Partin K.M., Mayer M.L. Negative allosteric modulation of wild-type and mutant AMPA receptors by GYKI 53655. Mol. Pharmacol. 49:1996;142-148.
20. Tarnawa I., Berzsenyi P., Andrasi F., Botka P., Hamori T., Ling I., Korosi J. Structure-activity relationships of 2,3-benzodiazepine compounds with glutamate antagonistic actions. Bioorganic Med. Chem. Lett. 3:1993;99-104.
21. Xue D., Huang Z.G., Barnes K., Lesiuk H.J., Smith K.E., Buchan A.M. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. J. Cerebral Blood Flow. Metab. 14:1994;251-261.
22. Zorumski C.F., Yamada K.A., Price M.T., Olney J.W. A benzodiazepine recognition site associated with the non-NMDA glutamate receptor. Neuron. 10:1993;61-67.